These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 26588892

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP, Robertson CA, Talbot HK, Decker MD.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):2058-2064. PubMed ID: 28700265
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, Matassa V, Leong J.
    Vaccine; 2017 Apr 04; 35(15):1856-1864. PubMed ID: 28302411
    [Abstract] [Full Text] [Related]

  • 7. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M.
    Vaccine; 2015 May 15; 33(21):2485-92. PubMed ID: 25843270
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
    Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA.
    Hum Vaccin Immunother; 2014 May 15; 10(5):1171-80. PubMed ID: 24609063
    [Abstract] [Full Text] [Related]

  • 9. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model.
    Chit A, Roiz J, Aballea S.
    PLoS One; 2015 May 15; 10(7):e0133606. PubMed ID: 26222538
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
    Pepin S, Dupuy M, Borja-Tabora CFC, Montellano M, Bravo L, Santos J, de Castro JA, Rivera-Medina DM, Cutland C, Ariza M, Diez-Domingo J, Gonzalez CD, Martinón-Torres F, Papadopoulou-Alataki E, Theodoriadou M, Kazek-Duret MP, Gurunathan S, De Bruijn I, GQM05 Study Group.
    Vaccine; 2019 Mar 22; 37(13):1876-1884. PubMed ID: 30558818
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
    Raviotta JM, Smith KJ, DePasse J, Brown ST, Shim E, Nowalk MP, Wateska A, France GS, Zimmerman RK.
    Vaccine; 2017 Oct 09; 35(42):5708-5713. PubMed ID: 28890196
    [Abstract] [Full Text] [Related]

  • 12. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
    Boikos C, Fischer L, O'Brien D, Vasey J, Sylvester GC, Mansi JA.
    Clin Infect Dis; 2021 Sep 07; 73(5):816-823. PubMed ID: 33605977
    [Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
    Pepin S, Szymanski H, Rochín Kobashi IA, Villagomez Martinez S, González Zamora JF, Brzostek J, Huang LM, Chiu CH, Chen PY, Ahonen A, Forstén A, Seppä I, Quiroz RF, Korhonen T, Rivas E, Monfredo C, Hutagalung Y, Menezes J, Vesikari T.
    Hum Vaccin Immunother; 2016 Dec 07; 12(12):3072-3078. PubMed ID: 27565435
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ, Falsey AR, Ozol-Godfrey A, Landolfi V, Tsang PH.
    Vaccine; 2015 Feb 25; 33(9):1151-9. PubMed ID: 25613721
    [Abstract] [Full Text] [Related]

  • 15. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
    Chit A, Roiz J, Briquet B, Greenberg DP.
    Vaccine; 2015 Jan 29; 33(5):734-41. PubMed ID: 25444791
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS, Noh JY, Lee J, Choi JY, Lee JS, Kim MS, Kim HS, Bang J, Lavis N, Kim WJ.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):587-592. PubMed ID: 28933625
    [Abstract] [Full Text] [Related]

  • 17. Quadrivalent inactivated influenza vaccine (VaxigripTetra™).
    Gresset-Bourgeois V, Leventhal PS, Pepin S, Hollingsworth R, Kazek-Duret MP, De Bruijn I, Samson SI.
    Expert Rev Vaccines; 2018 Jan 04; 17(1):1-11. PubMed ID: 29157068
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
    Airey J, Albano FR, Sawlwin DC, Jones AG, Formica N, Matassa V, Leong J.
    Vaccine; 2017 May 09; 35(20):2745-2752. PubMed ID: 28390934
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.